



Mr Arun Sawhney
CEO & Managing Director
Ranbaxy Laboratories Limited

Personal Profile:

Mr. Arun Sawhney joined Ranbaxy in May 2008 and was elevated to the position of President-Global Pharmaceutical Business in January 2010. He was appointed as Managing Director of the Company effective August 20, 2010, for a period of three years, and re-designated as CEO & Managing Director effective August 5, 2011. He was re-appointed as CEO & Managing Director of the Company for a period of five years effective January 1, 2012.

Mr. Sawhney is an industry veteran, with over three decades of international experience in the Chemical and Pharmaceutical arena. He has held senior functional and management positions in global pharmaceutical companies like Max-Gb, Hindustan Ciba-Geigy, Bayer India Limited and Dr. Reddy's Laboratories Limited.

Mr. Sawhney is one of the founder members of the Pharmaceuticals Export Promotion Council of India (Pharmexcil) and is currently a member of the Advisory Board of the United States Pharmacopeia (USP) in India. He is also the Chairman of the Confederation of Indian Industry (CII)'s National Committee on Pharmaceuticals and a Member of the India-Malaysia CEO Forum, the India-South Africa CEO Forum, the India-Russia CEO Forum, the BRICS Business Council and the India Africa Business Council constituted by the Government of India. Mr. Sawhney has been Chairman of the Pharmaceutical Committee of the Federation of Indian Chambers of Commerce and Industry (FICCI). He is also a member of the Academic Advisory Council of the International Management Institute (IMI), Delhi, India.

An alumnus of IMI, he graduated in Commerce from the Sydenham College of Commerce, Mumbai, India.

Company Profile:

Ranbaxy Laboratories Limited (Ranbaxy) is a research based international pharmaceutical company serving customers in over 150 countries. For more than 50 years, we have been providing high quality, affordable medicines trusted by healthcare professionals and patients across geographies.

Ranbaxy is a member of the Daiichi Sankyo Group. Daiichi Sankyo is a leading global pharma innovator, headquartered in Tokyo, Japan.

We have ground operations in 43 countries and 21 manufacturing facilities spread across 8 countries. We cover all the top 25 pharmaceutical markets of the world and have a robust presence across both developed and emerging markets.

Offering High Quality, Affordable Pharmaceuticals

We are a vertically integrated company that develops, manufactures and markets Generic,

Branded Generic, Value-added and Over-the-Counter (OTC) products, Anti-retrovirals (ARVs), Active Pharmaceutical Ingredients (APIs), and Intermediates. We have a large portfolio of over 500 molecules that cover multiple dosage forms including tablets, capsules, injectables, inhalers, ointments, creams and liquids. Our presence extends across therapies and includes Anti-infectives, Cardiovascular, Pain management, Central Nervous System (CNS), Gastrointestinal, Respiratory, Dermatology, Orthopaedics, Nutritionals and Urology. Biotech and Vaccines are two new segments that we have begun investing in. A stronger presence in these areas will add significant depth to the existing product pipeline.

Through our unique hybrid business model involving Daiichi Sankyo, we also introduce innovator products in markets around the world.

Driven by Innovation

Our continued focus on Research & Development (R&D) has resulted in several regulatory approvals in both developed and emerging markets. We have multiple R&D centres in Gurgaon, Haryana, India with facilities for generic and innovative research. Our scientists have given India its first New Chemical Entity (NCE) that was launched on April 25, 2012. The product, Synriam™, is a new age cure for Malaria. With a strong focus on research in generics, we are increasingly working on more complex and specialised areas.

Delivering Value

Our business philosophy, based on delivering value to our stakeholders, constantly inspires our people to innovate, excel and set new global benchmarks. Our multicultural workforce, comprising more than 14,600 employees of over 50 nationalities, gives us the strength to make quality healthcare accessible to people around the world. We remain committed to aggressively pursuing our mission of 'Enriching lives globally, with quality and affordable pharmaceuticals'.